primobolan dosage

At the beginning of therapy with simvastatin possible transient increase in the level of “liver” enzymes.
Before starting therapy and then regularly liver function tests (to monitor the activity of “liver” enzymes every 6 weeks during the first 3 months., And then every 8 weeks for the remainder of the first year, 1 and then every six months) and at higher doses of the test should be conducted to determine liver functions. By increasing the dose to 80 mg of the test should be carried out every 3 months. When persistent elevations of transaminases (3 times as compared to baseline) receiving simvastatin should be discontinued.
Simvastatin, like other inhibitors of primobolan dosage reductase inhibitors, should not be applied at an elevated risk of rhabdomyolysis and renal failure (on the background of severe acute infections, hypotension, planned major surgery, trauma, severe metabolic disorders).
Cancel lipid-lowering drugs during pregnancy has no significant impact on the long-term treatment of primary hypercholesterolemia.
in patients with low thyroid function (hypothyroidism) or the presence of certain diseases of the kidneys (nephrotic syndrome) with an increase in cholesterol levels should first carry out treatment of the underlying disease.
simvastatin with caution appoint primobolan dosage persons who abuse alcohol and / or have a history of liver disease.
Before and during treatment the patient should be on hypolipidemic diet.
Co-administration of grapefruit juice may enhance the severity of side effects associated with taking simvastatin should be avoided simultaneous reception.
simvastatin is not shown in those cases where there is hypertriglyceridemia I, IV and V types.
Treatment with simvastatin may cause myopathy, leading to rhabdomyolysis and renal failure. The risk of this disease increases in patients receiving simultaneously with simvastatin one or more of the following drugs: fibrates (gemfibrozil, fenofibrate), cyclosporine, nefazadon, macrolides (erythromycin, clarithromycin), antifungal agents of “azole” group (ketoconazole, itraconazole) and HIV protease inhibitors (ritonavir). The risk of myopathy is also increased in patients with severe renal insufficiency.
All patients who start therapy with simvastatin and patients who need to increase the dose of the drug should be warned of the possibility of myopathy and need immediate treatment to the doctor in case of unexplained pain, pain in muscle flaccidity or muscle weakness, particularly if accompanied by malaise or fever. Drug therapy should be discontinued immediately if myopathy is diagnosed or suspected.
In order to diagnose myopathy is recommended to conduct regular measurement.
In the treatment with simvastatin may increase the content , which should be considered when diagnosing differintsialnoy pain behind the breastbone. Drug withdrawal criterion is an increase in serum more than 10 times the upper limit of normal. Patients with myalgia, myasthenia and / or marked increase  drug treatment is stopped.
The drug is effective as a monotherapy, primobolan dosage or in combination with bile acid sequestrants.
In case of missing the current drug dose must be taken as soon as possible. When the time came the next dose, do not double the dose.
Patients with severe renal insufficiency treatment is carried out under the control of renal function.
The duration of the drug is determined by the physician individually. azab 500